Please assess the completion status of the following clinical trial:

Trial Title: 11C Topotecan PET Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ovarian cancer, small cell lung cancer, or other cancers~  * Metastatic brain disease~* Eligible for topotecan therapy~* Measurable disease by CT scan and/or MRI~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* More than 3 months~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Not specified~Renal~* Creatinine clearance ≥ 50 mL/min~Other~* Not pregnant or nursing~* Adequate end-organ function~* Able to tolerate lying on a radiology table for ≥ 1 hour~* No serious medical or psychiatric illness that would preclude study compliance or giving informed consent~PRIOR CONCURRENT THERAPY: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).